VLS Valneva SE

Valneva SE: declaration of shares and voting rights - November 2021

Valneva SE: declaration of shares and voting rights - November 2021

VALNEVA

Declaration of shares and voting rights

November 30, 2021

__________________________________________________________________________________________

Company name: VALNEVA

Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)

Regulated market of Euronext Paris - Compartment B

Declaration date: December 6, 2021

Number of shares

composing the share capital of Valneva 		Total number of voting rights including suspended voting rights* Description of the change Date on which this change was recognized Total number of voting rights excluding suspended voting rights**
 



105,086,163



 



   including:
  • 105,065,649 ordinary shares with a par value of €0.15 each; and
  • 20,514 preferred shares convertible into ordinary shares, with a par value of €0.15 each
 127,766,844 Transfer of 100 shares with double voting rights into bearer form



 



Double voting rights granted on 5,625 ordinary shares



 



Sale of 2,500 shares with double voting rights



  		 



 



November 10, 2021



 



 Between November 11 and November 15, 2021



 



November 30, 2021



 



 



  		127,642,522

Attachment



EN
06/12/2021

Underlying

VLSValneva SE

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Valneva SE

 PRESS RELEASE
Free
VLS VALNEVA SE

Declaration of voting rights - Valneva SE, March 2024

Declaration of voting rights - Valneva SE, March 2024 VALNEVA Declaration of shares and voting rights March 31, 2024__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: April 4, 2024 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the change Date on which this change was recognizedTotal number of voting right...

April 4, 2024 1 EN
 PRESS RELEASE
Free
VLS VALNEVA SE

Déclaration d'actions et de droits de vote de la société Valneva SE - ...

Déclaration d'actions et de droits de vote de la société Valneva SE - mars 2024 VALNEVA Déclaration d’actions et de droits de vote 31 mars 2024__________________________________________________________________________________________ Dénomination sociale : VALNEVAAdresse du siège social : 6 rue Alain Bombard, 44800 Saint-HerblainMarché réglementé Euronext Paris - Compartiment B Date de la déclaration : 4 avril 2024 Nombre d’actions composant le capital de Valneva Nombre total de droits de vote incluant les droi...

April 4, 2024 1 EN
Oscar Haffen Lamm
  • Oscar Haffen Lamm
VLS VALNEVA SE

VALNEVA: Initiates phase 1 trial of the Zika vaccine candidate

Valneva announced the initiation of the phase 1 trial of the Zika vaccine candidate (VLA1601), its 2nd generation adjuvanted inactivated vaccine, which will investigate its safety and immunogenicity. The phase 1 will enroll approx. 150 participants (18-49 years old) in the US who will receive a low

03/26/24 March 26, 2024 1 EN
 PRESS RELEASE
Free
VLS VALNEVA SE

Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Cand...

Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate Saint-Herblain (France), March 26, 2024 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the initiation of a Phase 1 clinical trial to investigate the the safety and immunogenicity of VLA1601, its second-generation adjuvanted inactivated vaccine candidate against the Zika virus (ZIKV). There are currently no preventive vaccines or effective treatments available against ZIKV. As such, this mosquito-borne disease remains a public health threat and is included in the Food and Dru...

March 26, 2024 1 EN
 PRESS RELEASE
Free
VLS VALNEVA SE

Valneva lance un essai de Phase 1 sur son candidat vaccin de deuxième ...

Valneva lance un essai de Phase 1 sur son candidat vaccin de deuxième génération contre le virus Zika Saint-Herblain (France), le 26 mars 2024 – (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui l’initiation d’un essai de Phase 1 pour évaluer l’innocuité et l’immunogénicité de VLA1601, son candidat vaccin inactivé et adjuvanté de deuxième génération contre le virus Zika (ZIKV). Il n'existe pas de vaccins préventifs ni de traitements efficaces contre le virus Zika qui demeure donc une menace pour la santé publique et a été inclus dans le pro...

March 26, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch